OctoPlus In Specialty Generic Pact

OctoPlus N.V. has signed a feasibility agreement with a leading generics company to develop a generic formulation of an existing injectable specialty pharmaceutical product. OctoPlus will develop a generic copy the injectable specialty pharmaceutical for small-scale production. If the project is successful, the contract may expand to a full process development and manufacturing agreement. Financial terms were not disclosed.

Jan Egberts, chief executive officer of OctoPlus, said, “Development of complex long-acting generic products, so-called specialty generics, is a strategic focus for OctoPlus. Our expertise in the development of these formulations is unique, and the combination of our formulation development and our manufacturing expertise really fits our sweet spot. This is the second specialty generic project which we have initiated and we look forward to putting our expertise to use for this project.”